Pharmaceutical company Elan and its partner Biogen have filed an investigational new drug application with the US Food and Drug Administration for Antegren for the treatment of rheumatoid arthritis.
The companies are hoping to start second phase clinical trials in the first half of this year. Rheumatoid arthritis affects around 5.8 million people worldwide.
Earlier this month, Elan and Biogen announced that third phase trials of Antegren for the treatment of Crohn's disease had been successful.
